Propanc Biopharma, Inc., was originally established on October 15, 2007 in Melbourne, Victoria, Australia. On November 23, 2010, the company was re-registered and re-registered in Delaware. They are a development-stage healthcare company currently focused on developing new cancer treatments for patients with pancreatic, ovarian and cancer. Using their scientific and oncology advisors, they developed a rational compounded formulation of anti-cancer compounds that work together in a variety of ways to control or prevent tumor recurrence and spread in the body. Their main product candidate, PRP, is a variant of their new formulation involving zymogen, the inactive precursor of the enzyme.
